Signal Detection and Clarification of Peripheral Neuropathy and Guillain-Barré Syndrome Associated with Exposure to Systemic Fluoroquinolones
Journal of Pharmaceutical Research International · pp. 407–417 · Published 17 Dec 2013
10.9734/BJPR/2014/6954Abstract
Aims: Peripheral neuropathy (PN) is an identified risk of systemic antibacterial therapy with fluoroquinolones. The risk and its severity, including the development of Guillain-Barré syndrome (GBS) between individual agents is uncertain. This study examines the association between fluoroquinolones and PN and GBS in cases spontaneously reported to the FDA Adverse Event Reporting System (FAERS). Study Design: Retrospective pharmacovigilance analysis. Place and Duration of Study: Cases submitted to FAERS between 1997 and 2012. Methodology: The MedDRA Preferred Term was used to define PN and GBS. Individual fluoroquinolones were identified by generic names and route of administration. Empirical Bayes Geometric Mean (EBGM) with 95% confidence interval (EB05-EB95) was calculated as disproportionality measure. Safety signals with EB05>2 was considered a significant disproportional increase in event reporting of at least twice times higher than expected. Results: There were 539 PN reports out of 46,257 adverse event reports submitted for fluoroquinolones. 9% of PN reports were for GBS. Significant disproportionality of PN (EBGM 2.70; EB05-EB95 2.51-2.90) and GBS (EBGM 3.22; EB05-EB95 2.55-4.02) was identified for fluoroquinolones. Signals of PN were detected for ciprofloxacin (EBGM 3.24; EB05-EB95 2.87-3.66) and levofloxacin (EBGM 3.36; EB05-EB95 3.02-3.72). A GBS signal was detected for ciprofloxacin (EBGM 4.15; EB05-EB95 2.94-5.74). GBS and PN respectively ranked 6th and 8th among reported neurological events. Conclusion: This study reemphasizes the link between fluoroquinolones and PN, and shows potential association with more severe forms of nerve damage, e.g. GBS. Unless the benefit of fluoroquinolone therapy outweighs PN risk, treatment with alternative antibacterial agents is recommended.
References (13)
- 1 Data Mining of the Public Version of the FDA Adverse Event Reporting System [DOI]
- 2 Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System [DOI]
- 3 Epidemiology of peripheral neuropathy. [DOI]
- 4 Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002 [DOI]
- 5 Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System [DOI]
- 6 Incidence and prevalence of CIDP and the association of diabetes mellitus [DOI]
- 7 Novel Statistical Tools for Monitoring the Safety of Marketed Drugs [DOI]
- 8 The role of databases in drug postmarketing surveillance [DOI]
- 9 Peripheral neuropathy: differential diagnosis and management.
- 10 Peripheral Insensate Neuropathy—A Tall Problem for US Adults? [DOI]
- 11 Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor [DOI]
- 12 Adverse drug reactions: Analysis of spontaneous reporting system in Europe in 2007–2009 [DOI]
- 13 Pharmacovigilance Analysis of Adverse Psychiatric Events and Suicidality Reported for Roflumilast, an Add-On COPD Therapy [DOI]
Cited by 1
Related research
- Accuracy of Monofilament in the Assessment of Diabetic Neuropathy — shares topic coverage
- Correlation between Corneal Sensitivity and Peripheral Neuropathy in Type 2 Diabetics Attending the Endocrinology Clinic of University of Port Harcourt Teaching Hospital (UPTH), Nigeria — shares topic coverage
- Thalidomide in SLE with Skin Damage Refractory to Other Treatment Options: Two Case Reports — shares topic coverage
- Glomus Tumor of Finger Often Misdiagnosed as Peripheral Neuropathy: A Case Report — shares topic coverage
- A Case Series on Total Ankle Arthroplasty Following High-Frequency Spinal Cord Stimulation in Peripheral Neuropathy Patients — shares topic coverage
Article metrics
Real usage data collected on this platform.
41
Page views
0
PDF downloads
4
Outbound clicks
1
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.